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PLINICAL RESEARCH Interventional Cardiology
ffect of Two Different Neuroprotection Systems
n Microembolization During Carotid Artery Stenting
ndrej Schmidt, MD, Klaus-Werner Diederich, MD, Susanne Scheinert, MD, Sven Bräunlich, MD,
atjana Olenburger, Giancarlo Biamino, MD, Gerhard Schuler, MD, Dierk Scheinert, MD
eipzig, Germany
OBJECTIVES This study sought to compare the efficacy of two different cerebral protection systems for the
prevention of embolization during carotid artery stenting (CAS) using a transcranial Doppler
(TCD) monitoring with the detection of microembolic signals (MES).
BACKGROUND Despite the introduction of cerebral protection systems, neurologic complications during
CAS cannot completely be prevented. Transcranial Doppler and detection of MES may aid
in assessing the efficacy of different neuroprotection systems.
METHODS A total of 42 patients with internal carotid artery stenoses were treated by CAS using either
a filter (E.P.I. FilterWire, Boston Scientific Corp., Santa Clara, California) (n  21) or a
proximal endovascular clamping device (MO.MA system, Invatec s.r.l., Roncadelle, Italy)
(n  21). Microembolic signal counts were compared during five phases: placement of the
protection device, passage of the stenosis, stent deployment, balloon dilation, and retrieval of
the protection device.
RESULTS There were no significant differences in clinical or angiographic outcomes between the two
groups. Compared to the filter device, the MO.MA system significantly reduced MES counts
during the procedural phases of wire passage of the stenosis, stent deployment, balloon
dilation, and in total (MES counts for the filter device were 25  22, 73  49, 70  31, and
196  84 during the three phases and in total, MES counts for the MO.MA system were
1.8  3.2, 11  19, 12  21, and 57  41, respectively; p  0.0001).
CONCLUSIONS In comparison to a filter device the MO.MA system led to significantly lower MES counts
during CAS. The detection of MES by TCD may facilitate the evaluation and comparison
of different neuroprotection systems. (J Am Coll Cardiol 2004;44:1966–9) © 2004 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.08.049American College of Cardiology Foundation
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1erebral protection devices have proven to be safe and
ffective in preventing distal embolization, according to
everal uncontrolled studies. However, neurologic compli-
ations cannot be prevented completely by these devices
1,2).
The most common neuroprotection systems include dis-
al filter devices or distal balloon protection systems. In
ontrast, proximal endovascular clamping devices such as
he MO.MA system (Invatec s.r.l., Roncadelle, Italy) estab-
ish cerebral protection by endovascular occlusion of the
xternal (ECA) and common (CCA) carotid artery, leading
o a cessation of flow in the target vessel (1,2).
We used transcranial Doppler (TCD) monitoring for the
etection of microembolic signals (MES) to evaluate and
ompare the efficacy of two different neuroprotection sys-
ems in preventing embolization during CAS.
ETHODS
tudy population. Between March 2002 and February 2003,
ES counts were determined during CAS in 42 consecutive
atients using either a FilterWire EX (E.P.I. FilterWire,
From the Division of Clinical and Interventional Angiology, Department of
ardiology, University of Leipzig–Heart Center, Leipzig, Germany.E
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ccepted August 16, 2004.oston Scientific Corp., Santa Clara, California) (n  21) or
he MO.MA system (n  21). All patients gave written
nformed consent for the intervention. Inclusion criteria were
ymptomatic stenoses of the internal carotid artery (ICA)
70% or asymptomatic stenoses 80%. Exclusion criteria for
he use of the MO.MA system were a severely diseased ECA,
hich precluded a safe placement of the system, or an
cclusion of the contralateral ICA. In all other cases the choice
f the protection device was at the discretion of the
nterventionalist.
tenting protocol. All procedures were performed via a
emoral approach. In the filter group, after placement of a
0-cm 7F sheath (Super Arrow Flex Sheath, Arrow Inter-
ational Inc., Bernville, Pennsylvania) into the CCA, the
tenosis was passed with the filter system and the filter was
ositioned in the distal portion of the ICA.
The MO.MA system integrates the functional aspects of
guiding catheter and cerebral protection incorporating two
eparately inflatable low-pressure elastomeric balloons for
ndovascular clamping of the ECA and CCA. An exit port
6-F) of the guiding catheter between the two occlusion
alloons enables the introduction of the angioplasty devices
Fig. 1). After insertion of the MO.MA system over an
1-F sheath (Fig. 2A), the distal balloon was inflated in the
CA and the proximal balloon in the CCA, blocking the
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November 16, 2004:1966–9 Microembolization During CASntegrade flow across the target vessel (Fig. 2B). A 0.014-in
uide wire (Galeo ES, Biotronik, Berlin, Germany) was
sed for wiring of the stenosis. In both groups, predilation
r direct stent implantation (Carotid Wallstent Monorail,
oston Scientific Corp., Natick, Massachusetts) was per-
ormed. All stents were post-dilated with a 5.0- or 6.0-mm
alloon (Submarine Rapido, Invatec s.r.l.), depending on
he vessel size. A specially manufactured retrieval catheter
as used for removal of the filter system. In the MO.MA
roup, potential debris was removed by blood aspiration of
0 to 60 ml via the guiding catheter before de-clamping of
he protection device. All procedures were performed in
ccordance with the guidelines of the institutional review
oards.
All patients received 75 mg clopidogrel and 100 mg
spirin daily at least three days before intervention, or 300
g clopidogrel and 500 mg aspirin intravenously before the
ntervention. In addition, all patients received 10,000 U of
eparin intravenously at the beginning of the procedure and
mg atropine before the first balloon dilation. An indepen-
ent neurologic examination, including the National Insti-
utes of Health Stroke Scale, was performed before and after
ll procedures.
etection of microembolic signals. Microembolic signals
ere detected using a multichannel transcranial Doppler
Multi-Dop X4, DWL, Sipplingen, Germany). A 2.0-
Hz transducer was fixed to the temporal bone for in-
onation of the ipsilateral middle cerebral artery. Microem-
olic signals were recorded during the whole procedure and
nalyzed offline by an experienced investigator according to
ecommended guidelines (3). Because the stenting protocol
ad to be provided to the investigator for matching the
ES to the procedural steps, the reviewer could not be
linded to the different protection devices in use. Microem-
olic signals were summarized for the following procedural
hases: 1) positioning of the protection device into the
Abbreviations and Acronyms
CAS  carotid artery stenting
CCA  common carotid artery
ECA  external carotid artery
ICA  internal carotid artery
MES  microembolic signals
TCD  transcranial Doppler
igure 1. Tip of the MO.MA system. Inflated common and external
arotid artery balloons for endovascular clamping and exit port of thee
uiding catheter. ACC  arteria carotis communis; ACE  arteria carotis
xterna.CA, 2) passage of the stenosis, 3) stent deployment, 4)
alloon dilation, and 5) retrieval of the neuroprotection
ystem. Injection of dye invariably leads to shower of MES
aused by microbubbles, which may be less hazardous then
olid particles (4). Phases of contrast injection were there-
ore excluded from the analysis.
tatistical analysis. Microembolic signal counts are given
s mean values SD. Microembolic showers are considered
0 MES per one second (5). Comparison of data was
erformed using the Student t test for continuous and
hi-squared test for categorical data.
ESULTS
atient characteristics were not different between the two
roups (Table 1). There were no significant differences in
ngiographic target lesion characteristics or angiographic
utcomes after CAS between the two groups (Table 2). All
AS were successful, leaving no residual stenosis 30%.
here were no post-procedural neurologic complications
xcept one transient ischemic attack with temporal weak-
ess of the right arm after CAS of a left ICA in the filter
roup. In one patient of each group, unconsciousness
ccurred during the intervention with immediate resolution
fter retrieval of the filter device or de-clamping of the
O.MA system. In both cases, CAS could be concluded
nder cerebral protection.
icroembolic signals. In the filter group, MES were
etected in all patients during all phases, except for one
atient during passage of the stenosis with the filter. In the
O.MA group, MES were detected in all patients during
he first and last phase of the procedure, but in a signifi-
antly lower number of patients during wiring of the
tenosis, stent deployment, and balloon dilation (Table 3).
ngiography revealed a superior thyroid artery originating
roximal of the ECA balloon in 11 patients of the MO.MA
roup. This anatomy did not correlate with the occurrence
f MES during the clamping period. In the filter group,
tent deployment and balloon dilation were associated with
ncreased MES counts. Compared to the filter group, the
O.MA system led to similar MES counts during the first
nd last phase, but were significantly reduced during wiring
f the stenosis, stent deployment, and balloon dilation and
n total (Table 4).
ISCUSSION
n the present study, TCD monitoring with detection of
ES was used to compare the efficacy of two different
oncepts of neuroprotection. Our study showed that CAS
sing the MO.MA system, a proximal endovascular clamp-
ng device, was accomplished with significantly lower MES
ounts compared to CAS using a filter system.
The first crucial step during CAS is the passage of the
tenosis with a guide wire or a distal protection device.
ranscranial Doppler and ex-vivo studies have shown thatmboli are frequently provoked during this step of the
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Microembolization During CAS November 16, 2004:1966–9rocedure (6,7). A potential advantage of proximal endo-
ascular clamping over distal filter or balloon devices is that
rotection is established before the stenosis is passed. In our
tudy, MES were highly significantly reduced during wiring
f the lesion using the MO.MA system compared with the
lter device.
Stent deployment and balloon dilation are the steps
onsidered to have the highest risk for distal embolization
uring the intervention (5,7). In our study, the use of the
O.MA system significantly reduced MES counts during
tent deployment and balloon dilation compared with a
lter device.
Another finding is that MES counts in the filter group of
ur series detected during stent deployment, balloon dila-
ion, and in total were of the same magnitude as the MES
igure 2. (A) MO.MA system placed into the external carotid artery (EC
he stenosis after clamping of the ECA and CCA. Abbreviations as in Fi
able 1. Patient Characteristics
Filter
Group
MO.MA
Group p Value
ge (yrs) 69  9 70  6 NS
ale gender, n (%) 16 (76) 18 (86) NS
ypertension, n (%) 19 (90) 19 (90) NS
iabetes, n (%) 9 (43) 9 (43) NS
yperlipidemia, n (%) 10 (48) 10 (48) NS
oronary artery disease, n (%) 15 (71) 16 (76) NS
ymptomatic stenosis, n (%) 6 (29) 7 (33) NSata are mean values  SD or n (%).
NS  not significant.
Dounts in unprotected CAS during the corresponding
hases and in total reported in another TCD study (5). This
nding could suggest that filters are not able to hold back
mboli, either because of insufficient vessel wall alignment
r because a considerable amount of emboli are too small to
e captured by these devices. In fact, it was shown that
undreds of thousands of microemboli100 m in size can
e shed during angioplasty with a potential to pass through
he pores of filter devices that range from 80 to 130 m,
eading to neurologic complications in an animal model (7).
Published results of studies using diffusion-weighted
agnetic resonance imaging after CAS are consistent with
ur findings. New cerebral lesions were seen in nearly 30%
f patients after mostly uncomplicated CAS without pro-
d common carotid artery (CCA); (B) 0.014-inch guidewire for passage of
1.
able 2. Lesion Characteristics and Procedural Data
Filter
Group
MO.MA
Group p Value
rade of stenosis (%) 85  8 86  9 NS
esion length (mm) 11  5 13  4 NS
alcification, n (%) 15 (71) 16 (76) NS
ccentricity, n (%) 11 (52) 12 (57) NS
lceration, n (%) 7 (33) 6 (29) NS
ontralateral stenosis 70%, n (%) 6 (29) 0 (0) 0.008
ontralateral occlusion, n (%) 2 (10) 0 (0) NS
acroscopic evidence of debris, n (%) 14 (67) 18 (86) NSata are mean values  SD or n (%).
NS  not significant.
t
u
m
fi
b
s
a
e
i
w
t
c
p
o
b
t
s
a
S
H
m
u
d
h
n
e
C
r
s
i
i
R
C
U
L
R
1
T
t
S
W
S
B
R
D
s
T
S
W
S
B
R
T
D
1969JACC Vol. 44, No. 10, 2004 Schmidt et al.
November 16, 2004:1966–9 Microembolization During CASection devices (8). However, new lesions were also seen in
p to 23% of the patients after protected CAS utilizing
ostly filter devices (9).
Another explanation for the high MES counts in the
lter group could be the inability of TCD to differentiate
etween gaseous and solid emboli (10). Although MES
howers caused by contrast injection were excluded from the
nalysis, some MES could represent less hazardous gaseous
mboli released from contrast or saline associated with the
nterventional equipment. Nevertheless, in a large registry
ith TCD performed in 263 CAS procedures, an associa-
ion of high MES counts with neurologic complications was
onfirmed (6).
It is difficult to explain the occurrence of MES during
rotection in the MO.MA group. A nonocclusive balloon
r a superior thyroid artery originating proximal of the ECA
alloon may lead to a continuous antegrade flow in the
able 3. Number of Patients (%) with Detectable MES During
he Different Phases of CAS
Filter
Group
MO.MA
Group p Value
heath placement-protection
device placement
21 (100%) 21 (100%) NS
iring of the stenosis 20 (95%) 6 (29%)  0.0001
tent deployment 21 (100%) 11 (52%) 0.0003
alloon dilation 21 (100%) 15 (71%) 0.008
etrieval of the protection
device
21 (100%) 21 (100%) NS
ata are mean values  SD or n (%).
CAS  carotid artery stenting; MES  microembolic signals; NS  not
ignificant.
able 4. MES Counts During the Different Phases of CAS
Filter
Group
MO.MA
Group p Value
heath placement-protection
device placement
20  15 18  10 NS
iring of the stenosis 25  22 2  3  0.0001
tent deployment 73  49 11  19  0.0001
alloon dilation 70 31 12  21  0.0001
etrieval of the protection
device
14  15 19  15 NS
otal 196 84 57  41  0.0001ata are mean values  SD or n (%).
Abbreviations as in Table 3.arget vessel during clamping. However, the latter condition
eems unlikely, as we found no correlation between this
natomic constellation and MES counts.
tudy limitations. Patient inclusion was nonrandomized.
owever, clinical and angiographic criteria were well
atched between the two groups. Only one filter device was
sed in our study. Other types of filter devices with
ifferences in pore size or alignment to the vessel wall may
ave generated different results. Because of the study size,
o conclusions can be drawn about differences in clinical
fficacy of the investigated protection devices.
onclusions. The MO.MA system led to a significant
eduction of MES compared with a filter device. This
uggests that the concept of proximal endovascular clamp-
ng has the potential to increase the safety of carotid
ntervention.
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